If you still have gas and diarrhea after a stomach virus that seemed to clear up weeks or even months ago, you are neither imagining it nor unusual. This is one of the most common reasons people end up in my clinic, and it has a name, a mechanism and, in most cases, a way out. It also has a handful of look-alike conditions that get missed for years, which is the part most articles skip.
What counts as normal recovery, and what does not
The vomiting and the worst of the diarrhea usually stop within two or three days. The lining of the intestine, however, takes considerably longer to rebuild than the symptoms take to settle, and during that window your digestion is genuinely not working at full capacity.
A practical timeline looks like this:
- Days 1 to 7. Loose stools, cramping, no appetite. Normal.
- Weeks 1 to 3. Bowel habit still unpredictable, more wind than usual, dairy and fatty meals feel heavy. Still normal, and usually the tail end of a temporary loss of the enzyme that digests lactose.
- Weeks 3 to 12. A slow return to baseline. Some people bounce back in days, others take the full three months. Still within the expected range.
- Beyond 3 months. This is the line. Symptoms that are still present at three months are no longer part of the infection, and this is the threshold used to diagnose post-infectious irritable bowel syndrome.2
One detail matters more than people expect: what you had is often not what you were told you had. "A stomach bug" covers norovirus, Campylobacter, Salmonella, Giardia and a dozen others, and the risk of lasting symptoms differs enormously between them. After a bacterial infection about 13.8 percent of people go on to develop irritable bowel syndrome. After a protozoan or parasitic infection it is 41.9 percent, three times higher.1 If your illness started abroad, that distinction is worth chasing, and our guide to traveler's diarrhea covers what to test for.
Why the symptoms persist once the germ has gone
This is the question that frustrates people most, because stool tests come back clean and they are told there is nothing wrong. There is something wrong. It is simply not an infection any more. The Rome Foundation's working team on post-infection IBS set out four mechanisms that are now reasonably well established.2
1. Low-grade inflammation that outlasts the infection
Biopsies taken from people months after gastroenteritis still show more immune cells in the gut lining than they should: activated lymphocytes, mast cells sitting close to nerve endings, and an increase in the hormone-producing enteroendocrine cells that help regulate transit. This is not the kind of inflammation that shows up on a colonoscopy. It is visible only under a microscope, which is precisely why a normal-looking scope does not mean nothing happened.
2. A microbiome knocked out of shape
An acute infection, and often the antibiotics given for it, reshuffles the bacterial population of the colon. Since most intestinal gas is produced by those bacteria fermenting carbohydrates that reach the colon undigested, a changed population means a changed gas output. It is worth knowing that antibiotic exposure around the time of the infection is itself an independent risk factor for developing IBS afterwards, raising the odds by about 70 percent.1 If your symptoms began with a course of antibiotics rather than the bug itself, read our article on antibiotic-associated diarrhea.
3. A gut that has turned its volume up
This is the one that explains the bloating best. Inflammation sensitises the nerve endings in the gut wall, a state called visceral hypersensitivity. The result is that a completely normal volume of gas, the same volume you carried before you were ill and never noticed, is now registered as pressure, distension and pain. Measurements confirm this: people with bloating usually have normal amounts of gas and an abnormal perception of it.8 If that is your dominant symptom, our dedicated guides to abdominal bloating and to constant gas go further into it.
4. A disturbed conversation between gut and brain
The gut and the central nervous system exchange signals continuously, and an infection disrupts that traffic in both directions. This is also why psychological distress at the time of the illness is one of the strongest predictors of what happens afterwards. Anxiety around the acute episode roughly doubles the risk of lasting symptoms, and a high somatic symptom score raises it fourfold.1 None of this means the symptoms are invented. It means the system that sets the gain on gut sensation was affected too, which is explained in more depth in our piece on the gut-brain axis. Under the new Rome V framework published in 2026, these conditions are classified as disorders of gut-brain interaction precisely because the problem sits in that two-way signalling rather than in any single organ.7
How common is this, really
The largest synthesis of the evidence pooled 45 studies and more than 21,000 people who had had infectious gastroenteritis.1 The numbers below come from that analysis and from two long-running outbreak cohorts, which are the closest thing we have to watching this unfold in real time.
Two findings deserve more attention than they usually get.
The first is that this is not only an IBS story. The Rome Foundation Global Epidemiology Study, published in 2026 and covering more than 54,000 people in 26 countries, found that about 1 in 10 people with a disorder of gut-brain interaction could trace it to an episode of gastroenteritis. Among those, the single most frequent pattern was not irritable bowel syndrome at all. It was functional dyspepsia, at 32.2 percent, ahead of IBS at 23.5 percent.3 That matches a separate meta-analysis showing that roughly 9.6 percent of people develop persistent upper-gut symptoms after gastroenteritis, with about two and a half times the risk of controls.6 So if your main complaint after the bug is fullness after a few mouthfuls, upper abdominal burning or nausea rather than diarrhea, that is a recognised outcome with its own management pathway, not a vague label.
The second is that the trigger matters enormously. In Bergen, Norway, a Giardia outbreak contaminated the water supply in 2004 and the affected residents were followed for a decade. Ten years later, 43 percent still met criteria for irritable bowel syndrome, against 14 percent of matched controls, and the figure had barely moved between years six and ten.5 By contrast, in Walkerton, Canada, where the outbreak was bacterial, the rate fell from 28.3 percent at two to three years to 15.4 percent at eight.4 A parasite leaves a deeper mark than a bacterium, and both leave a deeper mark than a virus.
Covid-19 belongs in this conversation too. A meta-analysis of 13 studies found post-infection IBS in about 7.2 percent of people after Covid-19 against 4.9 percent of controls, although the confidence intervals were wide and the certainty low.21 A multicentre cohort followed patients for a year and found that the small group who developed a post-Covid gut-brain disorder, around 4.5 percent, got steadily worse over twelve months while everyone else improved.22 It is a real phenomenon, but a less common one than the internet suggests.
It is not always post-infectious IBS: the four impostors
This is the part of the story I care about most, because post-infectious IBS is a diagnosis that gets handed out quickly and then never revisited. Gastroenteritis is common enough that it frequently coincides with, or unmasks, something else entirely. Four conditions account for most of the ones I find.
Bile acid diarrhea
Bile acids are meant to be reabsorbed at the end of the small intestine. When that process is disrupted they spill into the colon, where they act as a powerful laxative. It is far commoner than most patients are ever told: pooled data show bile acid malabsorption in about 28 percent of people carrying a diagnosis of diarrhea-predominant IBS.14 The clues are urgent, watery, often yellow or pale stools, frequently within an hour of eating and notoriously first thing in the morning, sometimes with a degree of urgency that dictates where people are willing to go. It matters because the treatment is specific and often works quickly: a bile acid sequestrant, whose efficacy was confirmed in a 2025 meta-analysis.15 Nothing in the standard IBS toolkit touches it.
Celiac disease, finally revealing itself
Celiac disease can stay quiet for years and then declare itself after a physiological stress such as an infection. Among people presenting with IBS-type symptoms, the pooled prevalence of biopsy-confirmed celiac disease is around 4 percent, roughly four times the background rate, which is why serology belongs in the first round of tests rather than the fifth.17 The one practical trap: you must still be eating gluten when the blood test is taken, otherwise it can come back falsely negative. Our celiac disease guide covers the testing sequence.
Microscopic colitis
Watery diarrhea, often several times a day and sometimes waking people at night, in a colon that looks completely normal at colonoscopy. The diagnosis exists only under the microscope, so it is missed unless biopsies are deliberately taken from a normal-looking bowel. It is commonest in people over 50, particularly women, and is associated with several widely used drugs. We cover it in detail in our guide to microscopic colitis.
The infection that never actually left
Giardia is the classic offender, because a single stool sample misses it often and the symptoms of chronic giardiasis are indistinguishable from post-infectious IBS. Clostridioides difficile is the other, especially if the original episode was treated with antibiotics; it causes a distinctive watery diarrhea that can relapse weeks after apparently successful treatment, and we cover it separately in our article on C. difficile. Both are curable. Neither responds to a low FODMAP diet.
The practical point
Post-infectious IBS is a diagnosis of exclusion, not a first guess. If you were given the label without a blood panel, celiac serology and a stool calprotectin, the label is not yet earned.
Red flags: see a doctor rather than waiting
These are not features of post-infectious IBS. Any one of them means the situation needs assessing, not monitoring.
- Blood in the stool, or black tarry stools. Never attribute this to a past infection. See blood in the stool.
- Unintentional weight loss, particularly more than 5 percent of your body weight.
- Diarrhea that wakes you at night. Functional symptoms characteristically let you sleep.
- Fever, or persistent vomiting, weeks after the acute illness.
- Anaemia, or a new iron deficiency on blood tests.
- Symptoms starting after the age of 45 to 50 with no previous history of a sensitive gut.
- A family history of bowel cancer, inflammatory bowel disease or celiac disease.
- Progressive symptoms. Post-infectious IBS fluctuates and slowly improves. Steady worsening is a different story.
Which tests are actually worth doing
The aim is not to test everything. It is to rule out the handful of conditions that are treatable and would otherwise be missed, and then stop. Both the American College of Gastroenterology and the British Society of Gastroenterology recommend a deliberately short panel for this situation.910
| Test | What it is for | Worth doing? |
|---|---|---|
| Full blood count, ferritin, CRP | Anaemia, iron deficiency, inflammation | Yes, in everyone |
| Celiac serology (tTG-IgA plus total IgA) | Celiac disease, four times commoner in this group | Yes, in everyone, while still eating gluten |
| Faecal calprotectin | Separates inflammatory bowel disease from a functional disorder | Yes. A normal result makes IBD very unlikely |
| Stool tests for parasites and C. difficile | An infection that was never cleared | Yes if travel, exposure, or antibiotics preceded it |
| Thyroid function | An overactive thyroid mimicking this picture | Reasonable, it is cheap and occasionally positive |
| Bile acid testing, or a therapeutic trial | Bile acid diarrhea, present in around a quarter of IBS-D | Yes if the diarrhea is urgent, watery and post-meal |
| Colonoscopy | Structural disease, plus biopsies for microscopic colitis | Only with red flags, age over 45 to 50, or a raised calprotectin |
| Food intolerance IgG panels | Nothing. They do not identify food intolerance | No. Not recommended by any guideline |
A word on calprotectin, because it is the test that saves most people a colonoscopy. Pooled across 17 studies it has a sensitivity of about 86 percent and a specificity of 92 percent for distinguishing inflammatory bowel disease from IBS. At the prevalence of IBD seen in this setting, a normal result carries a negative predictive value of 99.8 percent, which is about as reassuring as a non-invasive test gets. The same maths works in reverse: a mildly raised result is far more often a false alarm than Crohn's disease, so it needs interpreting rather than panicking over.16
What actually works
There is no drug licensed specifically for post-infectious IBS, and the Rome Foundation was explicit that no pharmacological strategy has been proven for it as a distinct entity.2 What we do have is good evidence from IBS as a whole, applied to whichever symptom bothers you most. Ranked by how much I rely on them:
Diet, as a time-limited experiment
A low FODMAP diet reduces the fermentable carbohydrates that reach the colon, which is exactly where the gas is made. In a network meta-analysis of 13 randomised trials it ranked first for global symptoms and, notably, was the only intervention superior to standard dietitian-led advice specifically for bloating and distension.11 A larger 2025 network meta-analysis of 28 trials confirmed that it remains among the most effective options and the only one clearly superior to a habitual diet for bloating, while also showing that a starch-reduced and sucrose-reduced diet performed well for overall symptoms in the two trials that tested it.12
Two caveats that matter more than the ranking. First, it is a four to six week diagnostic test followed by structured reintroduction, not a permanent way of eating; staying on it indefinitely narrows the diet and impoverishes the microbiome. Second, it is genuinely difficult to do properly without a dietitian, and done badly it produces all the restriction and none of the benefit.
Treating the specific cause you found
If the workup identified bile acid diarrhea, a sequestrant is the treatment and it often works within days.15 If it identified celiac disease, a gluten-free diet is the treatment. If it identified persistent giardiasis, an antiparasitic is. This is the single best argument for doing the tests properly at the start. A meaningful minority of people carrying a post-infectious IBS label turn out to have something specific and treatable instead, and none of it is visible without looking for it.
Neuromodulators, when pain is the problem
Low-dose tricyclics are the best-evidenced drug class here, and they are not being prescribed as antidepressants. At these doses they act on gut pain signalling and slow transit, which is useful when diarrhea predominates. ATLANTIS, the largest trial of a tricyclic ever conducted in IBS, randomised 463 patients in primary care and found low-dose amitriptyline clearly superior to placebo at six months, safe and well tolerated.18 A 2026 network meta-analysis of 68 trials placed tricyclics second overall among all neuromodulators and behavioural therapies, while being candid that the certainty of the evidence is low for most comparisons.19
Gut-directed behavioural therapy
Gut-directed hypnotherapy and cognitive behavioural therapy both outperformed control in that same 2026 analysis.19 These are not offered because the problem is psychological. They are offered because they demonstrably turn down visceral hypersensitivity, which is the mechanism generating the symptom. The practical obstacle is access, not evidence.
Rifaximin, in a narrow role
A poorly absorbed antibiotic that stays in the gut. In the TARGET trials, two weeks of rifaximin gave adequate relief of global IBS symptoms and bloating in significantly more patients than placebo.20 The effect is real but modest, the benefit fades over the following months, and it is a second-line option for selected people, not a routine step. It is emphatically not a reason to take repeated courses of ordinary antibiotics, which made things worse in the first place.
| Option | Best for | Evidence |
|---|---|---|
| Low FODMAP diet, then reintroduction | Bloating, gas, global symptoms | Strong. Ranked top for bloating in two network meta-analyses |
| Treating a specific cause found on testing | Whoever has one | Strong, and curative when it applies |
| Low-dose tricyclic | Pain, with diarrhea | Strong for IBS overall, from a large primary-care trial |
| Gut-directed hypnotherapy or CBT | Pain, hypersensitivity, quality of life | Moderate, limited mainly by availability |
| Rifaximin | Bloating in IBS without constipation | Moderate, modest effect, second line |
| Peppermint oil, antispasmodics | Cramping | Modest but safe, reasonable to try early |
| Probiotics | Marketed for everything | Weak. AGA recommends against outside a trial |
| Activated charcoal | Marketed for gas | No convincing evidence of benefit |
Five things you have probably been told that are not true
Will it go away?
Usually, yes, though more slowly than anyone would like. The Walkerton Health Study is the most informative source we have, because it followed an entire town that shared the same exposure on the same date. Among those who had had acute gastroenteritis during the outbreak, the prevalence of irritable bowel syndrome fell from 28.3 percent at two to three years to 15.4 percent at eight years. It remained about three times higher than in townspeople who had escaped the infection, but roughly half of those affected had recovered.4
The counterweight is Bergen, where the trigger was Giardia: 43 percent still had symptoms at ten years, essentially unchanged from year six.5 If a parasite started this, expect a longer road and a lower threshold for active treatment rather than watchful waiting.
What shifts the odds in your favour is not mysterious: identifying and treating a specific cause if there is one, a supervised dietary phase rather than an improvised one, addressing sleep and stress because they set the gain on gut sensation, and not cycling endlessly through supplements while the actual diagnosis goes unexamined.
How I approach this in clinic
The first consultation is mostly listening, because the pattern of the symptoms tells me more than any single test. Urgent watery stools within an hour of eating point one way. Fullness after three mouthfuls points another. Night-time diarrhea points somewhere else entirely and changes the plan on the spot.
Then a short, deliberate panel rather than a scattergun: bloods, celiac serology, calprotectin, and stool studies if the history justifies them. I would rather rule out the four impostors in one round than reassure someone twice and be wrong the third time. A colonoscopy is reserved for people whose history or results genuinely call for one, and when I do perform it in someone with watery diarrhea I take biopsies from normal-looking mucosa, because microscopic colitis is invisible otherwise. If you want to understand what a report already in your hands actually says, we have a guide to reading your endoscopy report.
And then we treat the mechanism we found, with a plan that has a review date attached to it. Most people are substantially better within three to six months. For persistent diarrhea with gas specifically, the approach I use is set out in detail in how I treat continuous diarrhea and gas in IBS-D, and the broader picture sits in our pages on irritable bowel syndrome and chronic diarrhea.
Symptoms lasting more than three months?
That is long enough to deserve an answer rather than reassurance. In-person in Madrid, or by video consultation from anywhere.
Book an AppointmentRelated reading
Most people with persistent symptoms after gastroenteritis never need an endoscopy. The job of the first consultation is to work out who does.
Frequently asked questions
How long is it normal to have gas and diarrhea after a stomach virus?
Most people are back to their usual bowel habit within one to two weeks. A tail of looser stools, extra wind and food sensitivity for three to six weeks is common and still counts as normal recovery. Once symptoms are still there beyond three months, they are no longer part of the infection and deserve a proper look. That is the point at which post-infectious irritable bowel syndrome is formally considered.
Do I need a colonoscopy for gas and diarrhea after gastroenteritis?
In most young adults with no alarm features, no. A short blood panel, celiac serology and a stool calprotectin usually settle the question, because a normal calprotectin makes inflammatory bowel disease very unlikely. A colonoscopy becomes the right test if you have blood in the stool, weight loss, anaemia, nocturnal diarrhea, onset after age 45 to 50, a raised calprotectin, or a family history of bowel cancer or inflammatory bowel disease. Watery diarrhea in someone over 50 also deserves biopsies to rule out microscopic colitis, which looks completely normal to the naked eye.
Are probiotics worth taking after gastroenteritis?
The honest answer is that the evidence is much weaker than the marketing. The American Gastroenterological Association reviewed the trials and recommended against using probiotics for irritable bowel syndrome outside a clinical trial, because the studies are small, use different strains and rarely agree with each other. They are safe for most healthy people, so a four-week trial of a single well-labelled product is reasonable if you want to try one. What is not reasonable is spending months and a lot of money on one product after another while the real cause goes unexamined.
Will post-infectious IBS ever go away?
For most people it fades. In the Walkerton cohort, which followed a whole town after a waterborne outbreak, the proportion with irritable bowel syndrome fell from 28.3 percent at two to three years to 15.4 percent at eight years, so roughly half recovered on their own over that period. Recovery is slower after a parasite such as Giardia, where 43 percent still had symptoms a decade later. The practical message is that time is on your side, but waiting passively is not a treatment plan.
References
- Klem F, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042-1054.e1. PubMed (opens in a new tab)
- Barbara G, et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. 2019;156(1):46-58.e7. PubMed (opens in a new tab)
- Marasco G, et al. Post-infection disorders of gut-brain interaction: results of the Rome Foundation Global Epidemiology Study. Gut. 2026;75(7):1297-1306. PubMed (opens in a new tab)
- Marshall JK, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605-611. PubMed (opens in a new tab)
- Litleskare S, et al. Prevalence of Irritable Bowel Syndrome and Chronic Fatigue 10 Years After Giardia Infection. Clin Gastroenterol Hepatol. 2018;16(7):1064-1072.e4. PubMed (opens in a new tab)
- Futagami S, et al. Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther. 2015;41(2):177-188. PubMed (opens in a new tab)
- Drossman DA, Chang L, Tack J. Disorders of Gut-Brain Interaction and the Rome V Process. Gastroenterology. 2026;170(6):1083-1098. PubMed (opens in a new tab)
- Moshiree B, et al. AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review. Gastroenterology. 2023;165(3):791-800.e3. PubMed (opens in a new tab)
- Lacy BE, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. PubMed (opens in a new tab)
- Vasant DH, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. PubMed (opens in a new tab)
- Black CJ, et al. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71(6):1117-1126. PubMed (opens in a new tab)
- Cuffe MS, et al. Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(6):520-536. PubMed (opens in a new tab)
- Su GL, et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):697-705. PubMed (opens in a new tab)
- Slattery SA, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42(1):3-11. PubMed (opens in a new tab)
- Dilmaghani S, et al. Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea. Aliment Pharmacol Ther. 2025;62(11-12):1054-1065. PubMed (opens in a new tab)
- Dajti E, et al. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults. Aliment Pharmacol Ther. 2023;58(11-12):1120-1131. PubMed (opens in a new tab)
- Ford AC, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009;169(7):651-658. PubMed (opens in a new tab)
- Ford AC, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773-1785. PubMed (opens in a new tab)
- Khasawneh M, et al. Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2026; published online ahead of print. PubMed (opens in a new tab)
- Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. PubMed (opens in a new tab)
- Mathur A, et al. Post-infection irritable bowel syndrome following Coronavirus disease-19: A systematic review and meta-analysis. Indian J Gastroenterol. 2024;43(3):557-566. PubMed (opens in a new tab)
- Marasco G, et al. Long-Term Impact of COVID-19 on Disorders of Gut-Brain Interaction: Incidence, Symptom Burden, and Psychological Comorbidities. United European Gastroenterol J. 2025;13(5):798-818. PubMed (opens in a new tab)